Welcome to our dedicated page for Alx Oncology Holdings SEC filings (Ticker: ALXO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for ALX Oncology Holdings Inc. (Nasdaq: ALXO), a clinical-stage biotechnology company developing investigational cancer therapies. Through these filings, investors can review the company’s official disclosures on financial performance, governance, risk factors and progress of its pipeline programs, including the CD47 inhibitor evorpacept and the EGFR-targeted antibody-drug conjugate ALX2004.
Annual reports on Form 10-K and quarterly reports on Form 10-Q typically describe ALX Oncology’s research and development activities, clinical trial portfolio, expenses related to programs such as evorpacept and ALX2004, and other information relevant to its status as a clinical-stage biotechnology company. These reports also discuss risks associated with drug development, regulatory approval and financing.
Current reports on Form 8-K are used by ALX Oncology to disclose material events. For example, the company has filed 8-Ks to furnish quarterly financial results and to announce changes in its board of directors and committee composition. Such filings may incorporate press releases as exhibits and provide timely updates on corporate developments.
Investors interested in insider transactions can review Forms 3, 4 and 5, which report holdings and changes in ownership by directors, officers and certain shareholders. Proxy statements on Schedule 14A offer additional insight into governance matters and executive compensation.
On Stock Titan, ALX Oncology’s SEC filings are updated as they become available from the EDGAR system. AI-powered tools can help summarize lengthy documents, highlight key sections and clarify technical language, making it easier to understand complex topics such as clinical trial disclosures, R&D spending and risk factor discussions related to the company’s oncology pipeline.
ALX Oncology Holdings Inc. ownership update: three Millennium-related filers and Integrated Core Strategies report shared beneficial interests in ALX Oncology common stock totaling reported holdings of 730,528 shares (0.5%) for Integrated Core Strategies and 1,988,559 shares (1.5%) for each of Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.
The filing is a Schedule 13G/A amendment that attaches a Joint Filing Agreement dated April 27, 2026 and explains the securities are held by entities subject to voting or investment discretion by Millennium-affiliated managers; the filing does not admit beneficial ownership by the reporting parties.
ALX Oncology Holdings Inc. is holding its 2026 annual meeting of stockholders as a virtual-only webcast on June 10, 2026 at 1:00 p.m. Pacific Time. Stockholders of record as of April 15, 2026, when 134,559,917 common shares were outstanding, may attend online, submit questions and vote.
Investors will vote on electing three Class III directors until 2029, an advisory “say‑on‑pay” approval of named executive officer compensation, and ratification of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The proxy also outlines board structure, director independence, committee roles, executive compensation philosophy and how to submit future stockholder proposals or director nominations.
ALX Oncology Holdings Inc. reported that Chief Development & Operating Officer Jeff E. Knight received a grant of stock options covering 800,000 shares of Common Stock. The options have an exercise price of $1.68 per share and expire on April 15, 2036.
According to the vesting terms, one-fourth of the options vest on April 13, 2027 and the remaining options vest in equal monthly installments over the following three years. After this grant, Knight holds 800,000 stock options directly.
ALX Oncology Holdings Inc reported that Chief Medical Officer Barbara Klencke received a grant of stock options covering 100,000 shares of Common Stock. The options have an exercise price of $1.68 per share and expire on April 15, 2036.
One-fourth of the option shares vest on February 25, 2027, and the remaining shares vest in equal monthly installments of 1/48th thereafter. This is a compensation-related award rather than an open-market stock purchase or sale.
ALX Oncology Holdings Inc identified Jeff E. Knight, its Chief Dev & Operating Officer, as a reporting person in a Form 3 insider filing. The data provided shows no reported purchases, sales, gifts, tax withholdings, restructurings, or derivative exercises, and no holdings are detailed.
ALX Oncology Holdings Inc. appointed Jeff Knight as Chief Development and Operating Officer, effective April 13, 2026. Knight is a veteran biopharmaceutical executive with more than three decades of experience in clinical development, regulatory affairs, and operational leadership at companies including Crinetics, Poseida, Halozyme, Amgen, Onyx, and Genentech.
Under his employment offer letter, Knight will receive an annual base salary of $565,000 and be eligible for an annual target cash bonus equal to 40% of base salary. He will also receive a stock option to purchase 800,000 shares of ALX Oncology common stock under the 2025 Inducement Equity Incentive Plan, vesting 25% after one year and the remainder in equal monthly installments over the following three years, subject to continued service.
He has entered into the company’s standard change of control and severance and indemnification agreements. A related press release highlighting his role in supporting upcoming clinical milestones for evorpacept and ALX2004 was furnished as an exhibit.
ALX Oncology Holdings director and chief executive officer Jason Lettmann reported an open-market sale of 12,311 shares of common stock at $2.17 per share on March 19, 2026. According to the filing, the shares were sold to satisfy his tax obligations related to the vesting of performance-based restricted stock units. After this transaction, he directly holds 293,609 shares of ALX Oncology common stock.
ALX Oncology Holdings Inc. senior vice president of finance and chief accounting officer Shelly Pinto reported a small open-market sale of common stock. On March 19, 2026, she sold 903 shares at $2.17 per share. According to the footnote, the shares were sold to satisfy her tax obligations related to the vesting of performance-based restricted stock units, indicating a tax-driven, routine transaction rather than a discretionary portfolio move. After this sale, Pinto directly holds 86,805 shares of ALX Oncology common stock.
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on cancer immunotherapies targeting the CD47 pathway and EGFR. It highlights evorpacept, a CD47 blocker with an inactive Fc domain designed to avoid blood toxicities seen in earlier CD47 drugs, and ALX2004, a novel EGFR-targeted antibody-drug conjugate.
Evorpacept has been studied in gastric, breast, lymphoma and multiple myeloma settings, often combined with antibodies such as trastuzumab, rituximab and zanidatamab. In gastric/GEJ cancer, adding evorpacept to standard HER2-directed therapy improved objective response rates and response duration, especially in tumors with high CD47 expression.
ALX2004, built with an in-house topoisomerase I payload and a matuzumab-derived antibody, showed strong preclinical tumor killing and bystander effect with encouraging non-human primate safety, and is now in a Phase 1 trial in EGFR-expressing solid tumors. As of June 30, 2025, non-affiliate common equity market value was $18.0 million, and 131,608,278 common shares were outstanding as of March 2, 2026.